

Pfizer Independent Medical Education Request for Proposals (RFP)

Community Oncology Support for Therapy Management in Multiple Myeloma (MM)

Competitive Grant Program – Pfizer Internal Review Process

Overview

This competitive grant program intends to provide an independent education grant to support to the formation of a new national collaborative initiative which will guide, support, and advise and discuss treatment management of MM patients receiving B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in the community cancer setting.

Geographic Scope/Location of Project

United States only

Project Types and Area of Interest

The successful proposal to this RFP will include multiple organizations collaborating together. For example, a collaborative proposal might include some or all of the following:

- Academic Cancer Center with experts in BCMA BsAbs
- Professional Medical Society with wide reach to community oncologists caring for patients with MM
- Medical Education company with strong logistical experience in conducting a national education program
- Patient Advocacy Organization to ensure all initiatives reflect the voice and needs of patients.

The initiative may include elements such as support for patient initiation and/or transition of care, optimization guidance for treatment management, support for initiation with guidance calls, on-call hours to resolve treatment related questions, and a forum to present cases, best practices and foster the creation of a community of BCMA BsAb treaters.

Key Milestones

- Application submission deadline: October 15, 2024
- Anticipated decision notification date: November 5, 2024
- Anticipated project start date: January 2025

Funding Range and Project Length

\$600,000 total - for 2-years of support



I. Eligibility

Geographic Scope/Location of Project:

United States only

Applicant Eligibility Criteria

- The following lead applicants may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an
 independent group of physicians not affiliated with a hospital, academic institution, or professional
 society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc.
- For projects offering continuing education credit, the requesting organization must be accredited.

II. Requirements

Date RFP Issued:

July 10, 2024

Clinical Area:

Oncology – Hematology – Multiple Myeloma

General Area of Interest for this RFP:

This RFP intends to support an organization interested in collaborating in the implemention of a new initiative that will guide, teach, and facilitate support for community oncologists and other healthcare professionals caring for MM patients receiving BCMA BsAbs.

The initiative should cover:

- Support for initiation of care
- Guidance on the patient transition to the community setting if treatment is initiated in an Academic Cancer Center
- Forum for best practices related to therapy management (e.g. Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, infections)

The initiative should be multi-faceted and may include education elements for all staff involved in the care of patients receiving BCMA BsAbs such as initiation calls, on-call hours to resolve questions, and a forum to present cases and best practices. Resources and tools might include implementation and discharge checklists, practice-guidance infographics, and information to provide to patients and caregivers. These are examples only and the applicant organizations are encouraged to include new creative ideas.



The successful proposal to this RFP will include multiple organizations collaborating together. For example, a collaborative proposal might include some or all of the following:

- Academic Cancer Center with experts in BCMA BsAbs
- Professional Medical Society with wide reach to oncologists caring for patients with MM
- Medical Education company with strong logistical experience in conducting a national education program
- Patient Advocacy Organization to ensure all initiatives reflect the voice and needs fo patients.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience:

• Oncologists and other healthcare professionals responsible for the care and treatment of patients with relapsed refractory multiple myeloma.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$600,000 will be considered. The estimated total available budget related to this RFP is \$600,000
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:

- RFP release date: July 10, 2024
- Grant Application due date: October 15, 2024
 Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: November 5, 2024
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: January 2025 to December 2026

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled. Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click "Create your password". [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]

- Click the "Start A New Knowledge Gap Application" button.
- In the application:
 - For the question "What type of request are you submitting?" select Response to a Request for Proposal (RFP)
 - For the question "Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?" select **Yes**
- Select the following Competitive Grant Program Name: 2024 ONC US Community Oncology Support for Therapy Management in MM IME
 - Select the following Primary Area of Interest: Oncology Hematology Multiple Myeloma
- Requirements for submission:



- Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (Jacqueline.Waldrop@Pfizer.com), with the subject line "Community Oncology Support for Therapy Management in MM"

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click <u>here</u> to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed
 unless a genuine conflict exists as between applicable law and the terms of the relevant grant
 agreement. Applicant is encouraged to share the core terms with counsel for approval prior to
 submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

Review and Approval Process:

 Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

References:

- Raje N, et al. Blood Cancer J. 2023;13(1):116.
- Otero P, et al. Lancet Oncol 2024; 25: e205–16
- Mohan M, et al. Blood Advances. 2022;6(8):2466–70.
- Lancman G, et al. Blood Cancer Discovery. 2023;4(6):440–51.
- Mohan M, et al. Br J Haematol. 2023;00:1-11.
- Ludwig H, et al. Lancet Oncol. 2023;24(6):e255-e269.
- NCCN. Prevention and Treatment of Cancer-Related Infections guidelines. V1.2023.
- Raje N, et al. Lancet Haematol. 2022;9(2):e143-e161.
- Hanna K, et al J Natl Compr Canc Netw. 2024; https://doi.org/10.6004/jnccn.2023.7184



About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.



Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project

Include a description of your organization's needs assessment for this proposed project which may
include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data
on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit
from the project outcomes. Describe the overall population size as well as the size of your sample
population.

Project Design and Methods

• Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation

Explain what measures you have taken to assure that this project is original and does not duplicate other
projects or materials already developed. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

• In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan

Describe how the project may have extended benefit beyond the grant. Will the teaching materials be
made available to others to use? Will there be tools or resources that are made publicly available
beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline

Provide an anticipated timeline for your project including project start/end dates.



Additional Information

• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

Describe the attributes of the institutions / organizations / associations that will support and facilitate the
execution of the project and the leadership of the proposed project. Articulate the specific role of each
partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
 - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
 - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.
 Please <u>click here</u> for details. General organizational running costs such as legal fees, insurance,
 heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs
 are not specific to a grant request and therefore, should not appear as line items in budgets.
 However, costs that are specific to the study (e.g., some countries require insurance to be taken out
 on a per-study basis for clinical research) would be acceptable to be included as line items.

